CME 
JOBS 
OUTBREAKS 
PEER-TO-PEER 
QUIZZES & QUESTIONS 
MEDTECH Publication: The Lancet
Design: Open-label, single-arm study of 157 patients who had undergone a median of six previous lines of therapy and who received at least one dose of teclistamab; 40 patients received the recommended phase II dose of teclistamab
Results: Of the 40 receiving the phase II dose, 58% achieved a very good partial response or better; 40% achieved a complete response or better
Peer-influenced content. Sources you trust. No registration required. This is HCN.
